BindingDB logo
myBDB logout

41 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
28085275 53 Structure-Based Design of Macrocyclic Factor XIa Inhibitors: Discovery of the Macrocyclic Amide Linker.EBI Bristol-Myers Squibb Company
27994741 48 Discovery of Phenylglycine Lactams as Potent Neutral Factor VIIa Inhibitors.EBI Bristol-Myers Squibb R&D
27455395 66 Discovery of a Highly Potent, Selective, and Orally Bioavailable Macrocyclic Inhibitor of Blood Coagulation Factor VIIa-Tissue Factor Complex.EBI Bristol-Myers Squibb R&D
27073051 71 Orally bioavailable pyridine and pyrimidine-based Factor XIa inhibitors: Discovery of the methyl N-phenyl carbamate P2 prime group.EBI Bristol-Myers Squibb Company
26871940 7 Definitive Metabolite Identification Coupled with Automated Ligand Identification System (ALIS) Technology: A Novel Approach to Uncover Structure-Activity Relationships and Guide Drug Design in a Factor IXa Inhibitor Program.EBI Merck Research Laboratories
26704266 80 Novel phenylalanine derived diamides as Factor XIa inhibitors.EBI Bristol-Myers Squibb Company
26318999 70 Development of a novel tricyclic class of potent and selective FIXa inhibitors.EBI Merck Research Laboratories
25978966 65 Development of a novel class of potent and selective FIXa inhibitors.EBI Merck Research Laboratories
26151189 56 Structure-Based Design of Macrocyclic Coagulation Factor VIIa Inhibitors.EBI TBA
26005539 23 Discovery of a Potent Parenterally Administered Factor XIa Inhibitor with Hydroxyquinolin-2(1H)-one as the P2' Moiety.EBI Bristol-Myers Squibb
25937013 40 Rapid development of two factor IXa inhibitors from hit to lead.EBI Merck Research Laboratories
25728130 79 Structure-based design of inhibitors of coagulation factor XIa with novel P1 moieties.EBI Bristol-Myers Squibb Company
24951330 25 Orally bioavailable factor Xa inhibitors containing alpha-substituted gem-dimethyl P4 moieties.EBI Bristol-Myers Squibb Company
25405503 109 Phenylimidazoles as potent and selective inhibitors of coagulation factor XIa with in vivo antithrombotic activity.EBI Bristol-Myers Squibb
25179681 81 Design, synthesis, and structure-activity and structure-pharmacokinetic relationship studies of novel [6,6,5] tricyclic fused oxazolidinones leading to the discovery of a potent, selective, and orally bioavailable FXa inhibitor.EBI Chinese Academy of Sciences
23294255 114 Development of new cyclic plasmin inhibitors with excellent potency and selectivity.EBI Philipps University Marburg
16644215 52 Design and synthesis of selective keto-1,2,4-oxadiazole-based tryptase inhibitors.EBI Celera Genomics
22770607 54 Potent direct inhibitors of factor Xa based on the tetrahydroisoquinoline scaffold.EBI Virginia Commonwealth University
20121198 63 Studies of benzothiophene template as potent factor IXa (FIXa) inhibitors in thrombosis.EBI Trigen Ltd.
18054227 45 Structure-activity relationship and pharmacokinetic profile of 5-ketopyrazole factor Xa inhibitors.EBI Bristol-Myers Squibb Research and Development
14640539 112 Discovery of 1-(2-aminomethylphenyl)-3-trifluoromethyl-N- [3-fluoro-2'-(aminosulfonyl)[1,1'-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor(1).EBI Pharmaceutical Research Institute
11170646 106 Discovery of 1-[3-(aminomethyl)phenyl]-N-3-fluoro-2'-(methylsulfonyl)-[1,1'-biphenyl]-4-yl]-3-(trifluoromethyl)-1H-pyrazole-5-carboxamide (DPC423), a highly potent, selective, and orally bioavailable inhibitor of blood coagulation factor Xa.EBI DuPont Pharmaceuticals Company
20650636 118 Discovery of a factor Xa inhibitor (3R,4R)-1-(2,2-difluoro-ethyl)-pyrrolidine-3,4-dicarboxylic acid 3-[(5-chloro-pyridin-2-yl)-amide] 4-[[2-fluoro-4-(2-oxo-2H-pyridin-1-yl)-phenyl]-amide] as a clinical candidate.EBI F. Hoffmann-La Roche Ltd
20355714 26 Discovery of a tetrahydropyrimidin-2(1H)-one derivative (TAK-442) as a potent, selective, and orally active factor Xa inhibitor.EBI Takeda Pharmaceutical Company Ltd.
20121197 148 Structure based drug design: development of potent and selective factor IXa (FIXa) inhibitors.EBI Trigen Ltd.
18674905 58 Factor VIIa inhibitors: target hopping in the serine protease family using X-ray structure determination.EBI Chugai Pharmaceutical Co., Ltd
16487703 4 Discovery of novel hydroxy pyrazole based factor IXa inhibitor.EBI Celera Genomics
16213711 37 Ketene aminal-based lactam derivatives as a novel class of orally active FXa inhibitors.EBI Bristol-Myers Squibb Pharmaceutical Research Institute
19884013 98 5-Vinyl-3-pyridinecarbonitrile inhibitors of PKCtheta: optimization of enzymatic and functional activity.BDB Wyeth Research
19842661 140 Discovery of 3H-benzo[4,5]thieno[3,2-d]pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in moloney murine leukemia virus (PIM) kinases.BDB Abbott Laboratories
19699645 12 Design, synthesis, and biological evaluation of hydroquinone derivatives as novel inhibitors of the sarco/endoplasmic reticulum calcium ATPase.BDB Northern Kentucky University
19428244 60 Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics.BDB GSK